FDA rejection raises serious questions for Momenta

The fallout over the FDA's rejection of Momenta's generic version of Lovenox--a rare setback for any developer--is continuing to dent the drug developer's reputation. Analysts have zeroed in on the implications the rejection has for Momenta's whole approach to development. As Cowen & Co. analyst Eric Schmidt noted, "We expect investors to be skeptical around Momenta's entire technology platform, pipeline and complex generic strategy." Ouch.

- read the report from The Wall Street Journal
- take a look at yesterday's release on the rejection

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.